# Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct05128734/  
OnCo record `nct05128734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of temozolomide and olaparib in triple-negative breast cancer, run by AHS Cancer Control Alberta, not yet recruiting.

## Summary

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) is a phase 2, randomised interventional study registered as NCT05128734 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-04-01 and due to reach its primary completion in 2028-04-01. Interventions recorded: Temozolomide; Olaparib. Conditions listed: Breast Cancer Triple Negative. Triple-negative eligibility wording from the registry: "* Female or male patients with triple negative breast cancer confirmed by pathology of the primary tumour or metastatic biopsy sample". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05128734
- Phase: 2
- Setting: A Randomized Phase II Study of Temozolomide Monotherapy or in Combination With Olaparib in Patients With METHYLATED 06-Methylguanine-DNA Methyltransferase (MGMT) Pre-Treated Triple Negative Breast Cancer (TNBC)
- Sponsor: AHS Cancer Control Alberta
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05128734: https://clinicaltrials.gov/study/NCT05128734

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05128734.json